151 articles - From Friday Jan 10 2025 to Friday Jan 17 2025
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Clin Gastroenterol Hepatol |
|---|
Non-colorectal Cancer Screening and Vaccinations in Patients with Inflammatory Bowel Disease: Expert Review. All adult patients with IBD should be screened for depression and anxiety annually. Patients who screen positive for depression or anxiety should be referred to the appropriate specialist, be it their primary care physician or a mental health specialist. |
meta-analyses and systematic reviews
| Aliment Pharmacol Ther |
|---|
Meta-Analysis of Placebo-Treated Patients: Dropout Rates From Treatment in MASH Randomised Controlled Trials. Placebo dropout in MASH RCTs is significant, mainly due to patient choice. Factors such as trial phase and treatment duration should be considered when calculating sample size in future clinical trials. |
Meta-Analysis: Exclusive Enteral Nutrition in Adults With Ulcerative Colitis. EEN was well tolerated with low therapy discontinuation in adults with active ulcerative colitis. However, there is insufficient evidence to support the use of EEN as an adjunctive therapy to standard of care. Further, well-designed studies with reproducible methodology and endpoints are necessary to evaluate its effectiveness. Registry number for systematic review PROSPERO 2022 CRD42022319584. |
| Endoscopy |
Endoscopic size measurement of colorectal polyps: a systematic review of techniques. While biopsy forceps, snare, and graduated devices can improve the accuracy of visual size estimation, their clinical implementation is limited by practical, time, and cost challenges. Computer-based techniques will likely offer improved accuracy of polyp sizing in the near future. |
| J Neurogastroenterol Motil |
Effect of Buspirone on Upper Gastrointestinal Disorders of Gut-Brain Interaction: A Systematic Review and Meta-analysis. We found that buspirone did not improve functional dyspepsia symptoms more than placebo, though studies were small. Buspirone showed benefit for bloating severity, albeit based on few studies. Larger and longer trials of buspirone, targeting more defined groups such as patients with bloating, are warranted. |
Efficacy of Amitriptyline in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Amitriptyline was found to be well-tolerated and effective in treating IBS compared to placebo. These findings support the use of amitriptyline for the management of IBS, particularly among patients with the IBS diarrhea subtype. Future research should focus on the dose-dependent effects of amitriptyline in IBS to better guide clinicians in personalized titration regimens. |
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study. Drug clearance was strongly influenced by serum albumin. Baseline clearance predicted deep biochemical remission at Week 30. Further investigation is needed to better understand optimal dosing strategies-especially for lower-weight children receiving vedolizumab. |
Blood Group B May Reduce Risk of Rebleeding in Patients With Upper Gastrointestinal Haemorrhage due to Peptic Ulcer Disease. Blood group B was associated with reduced risk in the composite outcome of rebleeding, need for surgery or embolisation and mortality (OR 0.15, 95% CI 0.04-0.63, p = 0.009). Blood group B was protective against rebleeding compared to non-blood group B (OR 0.20, 95% CI 0.05-0.84, p = 0.028). |
COLOFIT: Development and Internal-External Validation of Models Using Age, Sex, Faecal Immunochemical and Blood Tests to Optimise Diagnosis of Colorectal Cancer in Symptomatic Patients. For approximately 100,000 people per year with symptoms of suspected CRC, we predict it might save > 4500 colonoscopies with no evidence that more cancers would be missed if we used our model compared to using FIT f-Hb ≥ 10 μg/g. Including age, sex, MCV, platelets and f-Hb in a survival analysis model to predict the risk of CRC yields greater diagnostic utility than a simple binary cut off f-Hb ≥ 10 μg/g. |
Clinical Trial: Study to Investigate the Efficacy and Safety of the Alpha-2-Delta Ligand PD-217,014 in Patients With Irritable Bowel Syndrome. This first large, dose-ranging trial examining the efficacy of PD-217,014 showed no significant efficacy in participants with IBS or bowel habit sub-types, irrespective of their pain and anxiety levels. |
Current Burden of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease Among US Adults, 2017-2023. Specifically, the prevalence was 9.3% for lean MASLD, 1.3% for MetALD and 1.0% for ALD. Notably, within the MASLD group, significant fibrosis, advanced fibrosis, and cirrhosis were observed in 5.6%, 2.4% and 2.0%, respectively. |
Early Dynamics of Portal Pressure Gradient After TIPS Insertion Predict Mortality. Lack of increased ΔPPG post-TIPS insertion identifies a high-risk patient group with worse survival. We propose incorporating this second PPG measurement and determining ΔPPG into clinical practice to identify these patients early and tailor post-TIPS patient care. |
Use of a Non-Endoscopic Capsule-Sponge Triage Test for Reflux Symptoms: Results From the NHS England Prospective Real-World Evaluation. Capsule sponge triage is feasible, safe and acceptable. It substantially reduces the endoscopy burden for routine reflux referrals with a favourable diagnostic yield for Barrett's oesophagus. Longer term follow-up will help to confidently assess the impact of the programme and place of capsule sponge in the diagnostic pathway. |
| Am J Gastroenterol |
"INSERT-COIN": A PROSPECTIVE STUDY OF COIN INGESTION IN CHILDREN OF SOUTHERN ITALY. When coins are trapped in the middle/lower esophagus, we suggest withholding the procedure for at least 6-12 hours, especially for older children, as ⅔ pass spontaneously, not requiring endoscopic removal. |
Adaptive Behaviors, Esophageal Anxiety and Hypervigilance Modify the Association Between Dysphagia Perception and Histological Disease Activity in Eosinophilic Esophagitis. Higher esophageal anxiety, hypervigilance and use of adaptive behaviors are associated with active EoE and represent clinical markers of HDA. Adaptive behaviours provide complementary clinical information that is not detected by symptoms alone. The assessment of anxiety, hypervigilance, and adaptive behaviors improves the correlation between clinical and HDA in EoE. |
Cardiovascular Risk from Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factor Count, and Their Longitudinal Changes: A Nationwide Cohort Study. MASLD status, cardiometabolic risk factor count, and their longitudinal changes were al associated with the risk of incident CVD. Accurate identification of these markers may facilitate personalized management of MASLD-related CVD risk. |
Clinical Outcomes in A Multi-center Cohort Involving 919 Patients with Hypertriglyceridemia-associated Acute Pancreatitis. Using a multi-center cross-regional cohort, we demonstrated that HTG-AP had a higher risk of developing severe AP and organ failure. A risk prediction model for predicting severe AP was developed and effectively stratified patients. |
Colorectal cancer screening based on predicted risk: a randomized controlled trial. In a population not known to be at elevated CRC risk, brochures providing personalized CRC risk and screening recommendations improved risk-appropriate screening without impacting overall screening uptake. This approach could be helpful for aligning screening methods, risks, and benefits with cancer risk and resource allocation. |
Identifying and treating metabolic dysfunction-associated steatotic liver disease among at-risk Veterans. Few at-risk Veterans carried a MASLD diagnosis or had undergone staging elastography. Because MASLD diagnosis was associated with linkage to hepatology care and weight loss therapy services, implementation of population screening and management services for MASLD is critically needed. |
Increased medication utilization precedes incidentally diagnosed inflammatory bowel disease: a multicenter, case-control study. Asymptomatic patients showed a higher use of cardiovascular, antiparasitic, musculoskeletal, respiratory, and sensory organ medications up to five years before diagnosis. This trend suggests that a systemic inflammatory process occurs years before clinical onset of IBD, suggesting the potential for earlier diagnosis and intervention. |
Infliximab and adalimumab in the treatment of fistulizing Crohn's disease: a propensity score-matched analysis from the prospective Persistence Australian National IBD Cohort (PANIC4) study. The PANIC cohort with real-world data of non-hierarchical prescribing of biological agents supports the superiority of infliximab over adalimumab in bio-naïve FCD patients, but did not show a therapeutic difference in bio-exposed FCD. Thiopurine co-therapy was independently associated with improved biological agent persistence in FCD. |
Longitudinal associations between metabolic dysfunction-associated steatotic liver disease (MASLD) and subclinical cardiovascular measures in Chinese children. These findings support the clinical utility of MASLD in predicting the development of subclinical cardiovascular damages in childhood. |
Multi-target Stool DNA Testing for Colorectal Cancer Screening in Clinical Practice. Only 54.7% of patients completed their mt-sDNA test order. Older individuals were more likely to complete testing and test positive. Black patients were less likely to complete testing and, unexpectedly, less likely to test positive. Further exploration of mt-sDNA utilization including better understanding of the determinants of uptake, appropriateness, and evaluation of outcomes at colonoscopy is needed. |
Obesity is Independently Associated with Increased Risk of Fecal Incontinence and Altered Rectal Sensitivity. Classes II+III obesity was an independent risk factor for FI. Among patients with FI, increasing BMI and class II+III obesity were associated with altered rectal sensitivity. Anorectal function testing should be considered to help guide management of FI among patients with obesity. |
Oral microbiome dysbiosis is associated with precancerous lesions and disorders of upper gastrointestinal tract: A population-based study. Dysbiosis of the saliva microbiota is linked to various UGI disorders. However, microbiota dysbiosis in subgingival and buccal mucosa sites are specifically associated with the pre-malignant conditions Barrett's esophagus and gastric atrophy. The oral microbiome, particularly in the subgingival location, might act as biomarkers for UGI cancers. |
Risk of cancer and reoperation after ileorectal anastomosis and ileal pouch-anal anastomosis in familial adenomatous polyposis. Over the last three decades, few patients were diagnosed with cancer in the rectum or rectal cuff/pouch after (procto)colectomy in FAP. This might be due to an improved selection of the type of (procto)colectomy and close endoscopic surveillance including prophylactic polypectomies. |
Rome IV functional defecation disorder: time for a change in symptom criteria for improved clinical relevance? Rome IV symptom criteria need revision to include more defecatory symptoms, include al subtypes of IBS, and be inclusive of those with either loose stools or more frequent stools such as those previously labelled with "pseudodiarrhea" or "hyperdefecation". Continuing to include physiology criteria in the Rome diagnosis of FDD appears valid. |
SAFETY, PHARMACOKINETICS, AND CLINICAL EFFICACY OF ADS051, A NEUTROPHIL MODULATOR, IN ULCERATIVE COLITIS: RESULTS OF A RANDOMIZED PHASE 1B TRIAL. Phase 1b data in patients with UC indicate a favorable safety profile for ADS051 with encouraging signals of clinical activity, supporting the advancement to a Phase 2 trial. |
Study of the cortico-anorectal neurophysiology in women with fecal incontinence. Women with FI show significant neuropathy in the cortico-spino-anorectal pathway linked to impaired anorectal function. These findings underscore the brain-gut axis's role in FI pathophysiology, advocating for advanced neurophysiological diagnostics and targeted interventions. |
The Effect of Low-dose Aspirin on Disease Activity in Pregnant Individuals with Inflammatory Bowel Disease. Approximately one-third of patients with IBD cared for in a MFM practice were prescribed LDA during pregnancy. The use of aspirin among pregnant patients with IBD was not associated with an increased risk of disease activity. |
| Endoscopy |
Randomized comparison of precut papillotomy and endosonography guided rendezvous procedure for difficult biliary access in Malignant distal biliary obstruction. Both PcP and EUS-RV have comparable success, AER, mortality, and LOS. EUS RV could be used as an alternative to PcP in patients with malignant distal biliary obstruction and DBC. |
Safety and Effectiveness of EUS-Guided Gallbladder Drainage in Patients with Cirrhosis: An International Multicenter Experience. Our international multicenter experience suggests EUS-GBD is safe and effective in patients with cirrhosis, with outcomes similar to patients without cirrhosis when performed by experienced echoendoscopists. Patients with cirrhosis and symptomatic gallbladder disease can be considered for EUS-GBD. |
| Gastroenterology |
Mechanistic implications of the Mediterranean diet in patients with newly diagnosed Crohn's disease- multi-omic results from a prospective cohort. Adherence to MED is associated with beneficial clinical outcomes and decreased inflammatory markers. These may be driven by lower levels of primary bile-acids and microbial dysbiosis and a beneficial microbial and metabolite composition. Randomized controlled trials are needed to evaluate the role of MED in CD management. |
Risk of colorectal cancer associated with frequency of colorectal polyp diagnosis in relatives. A higher frequency of colorectal polyp diagnosis in relatives is associated with a greater risk of CRC, especially early-onset CRC. This risk is independent of number of affected relatives or youngest age at polyp diagnosis. These findings underscore the need for more personalized CRC screening strategies that are tailored to individuals with a family history of polyp. |
| Gastrointest Endosc |
British Society of Gastroenterology National Evaluation of Colonoscopy Quality: Findings from the National Endoscopy Database. UK colonoscopy quality has improved, yet almost 40% of endoscopists still fell short of minimum standards. Variation in quality was strongly associated with endoscopist procedure volumes; mandating minimum annual procedures and emphasising longer withdrawal times could improve overall quality. |
Endoscopic Ultrasound-Guided Drainage of Intra-Abdominal Abscess Using 15-mm vs. 10-mm Lumen-Apposing Metal Stents: An International Case-Matched Study. Both sizes showed comparable clinical success and safety profiles, with a significant trend of the need for fewer endoscopic procedures with the 15-mm LAMS. |
Quadrant, necrosis, and infection criteria for the risk stratification of walled-off necrosis: external validation using multi-institutional data. The QNI criteria effectively stratified time to clinical success and the risk of adverse outcomes for patients receiving EUS-PFD of WON. Further investigations could elucidate appropriate management strategies based on QNI-based risk stratification. |
The Clinical Utility of Incorporating Next-Generation Sequencing Results in the Management Algorithm of Pancreatic Cysts. NGS informed surgical decision-making, cyst type differentiation, and evaluation of pancreatic duct dilation, leading to changes in management. Indeed, NGS emerges as a useful tool in select patients with pancreatic lesions by improving diagnostic precision and guiding patient care paths. |
| Gut |
Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU. Anti-TNF withdrawal in selected patients with IBD in clinical, endoscopic and radiological remission has no impact on sustained clinical remission at 1 year although objective markers of activity were higher in patients who withdrew treatment. |
| Hepatology |
CD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease. Human and experimental evidence supports CD44 as a marker of hepatic inflammation in ALD. In addition, CD44 modulates neutrophil mobilization and functions and its targeting partially prevents liver inflammation and injury in the context of acute-on-chronic alcohol drinking. |
Comparing the cost of cirrhosis to other common chronic diseases: A longitudinal study in a large national insurance database. The cost of care for cirrhosis is high, significantly higher than HF and COPD. Interventions directed at optimizing care to prevent progression to cirrhosis and decompensation are likely to alleviate this public health burden. |
Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multi-center prospective cohort study. Despite higher HCC recurrence and lower ITT survival in AC, post-LT survival was comparable between UNOS-DS and AC. Y-90 attained higher DS success than TACE in AC. LT after downstaging is feasible in AC, though defining an upper limit in tumor burden may be necessary. |
End-procedural adherence to recommended hemodynamic targets does not improve the outcome of elective tips in cirrhotic patients. AHR measured at the end of an elective TIPS may not be essential to define the eventual outcome, while a marked drop in PCPG could negatively affect the prognosis of patients with RA. |
Identification of optimal portal pressure decrease to control ascites while minimizing hepatic encephalopathy after TIPS: A multicenter study. A targeted PPG reduction of 60-80% showed significantly reduced HDA without increased oHE risk. Therefore, PPG reduction within this range could be a valid reduction target. |
In vivo selection of hepatocytes. Finally, recent work has shown that somatic mutations produce clonal expansion of injury-resistant hepatocytes in most chronic liver diseases. In this review, we will address the role of hepatocyte selection in disease pathophysiology and therapeutic strategies. |
Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure. Baveno VII criteria to exclude (FU-liver stiffness measurement 3 y). One-time post-treatment risk stratification based on noninvasive criteria provides important prognostic information that is maintained during long-term follow-up, as the hazards remain proportional over time. |
Longitudinal response to standard of care in pediatric metabolic dysfunction-associated steatotic liver disease: Rates of improvement and worsening, and factors associated with outcomes. This study developed criteria for improvement and worsening in children with MASLD over one and two years of follow-up. With SOC, over one-quarter of children are likely to improve while one-fifth of children are likely to worsen. Targeting interventions that affect BMI and lipid parameters may help improve MASLD over time. |
The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects. In this review we aim to provide the most recent evidence on the immunopathogenesis of PBC. We will analyse the immune function of the biliary epithelium, assessing the immunomodulatory functions of the bile acids and the evidence of the immunological roles of the secretory pathways targeted by the current treatments. |
Ubiquitination of TFEB increased intestinal permeability to aggravate metabolic dysfunction-associated steatohepatitis. The ubiquitination of TFEB plays a pivotal role in increasing intestinal permeability and promoting the progression of MASH by inhibiting autophagy. Intestinal TFEB may represent a novel therapeutic target for the treatment of MASH. |
| J Hepatol |
AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials. AZD2693 reduced liver PNPLA3 with an acceptable safety and tolerability profile. These findings support the continued development of AZD2693. Clinical trial number NCT04142424, NCT04483947 IMPACT AND IMPLICATIONS Clinical treatment options for MASH are limited. The genetic risk factor with the largest effect size for progressing to poor liver-related outcomes in MASH is a single-nucleotide polymorphism in the gene PNPLA3 (p.I148M). In Phase 1 SAD and MAD studies, AZD2693, a liver-targeted antisense oligonucleotide was well tolerated, reduced liver PNPLA3 mRNA and protein levels, and dose dependently reduced liver fat content in homozygous PNPLA3 148M risk allele carriers. These data support continued development of AZD2693 as a potential precision medicine treatment for MASH. The Phase 2b FORTUNA study is now ongoing. |
Circulating monocytes upregulate CD52 and sustain innate immune function in cirrhosis unless acute decompensation emerges. CD52 may represent a biologically relevant target for future immunotherapy. Stabilising CD52 may enhance monocyte functions and infection control in the context of cirrhosis, guided by sCD52/PLC as biomarkers indicating immuneparesis. Impact and implications Monocyte dysfunction substantially contributes to infection susceptibility which determines the prognosis of cirrhosis patients, and represents a critical condition with unmet therapeutic needs. Its underlying mechanisms remain poorly understood, although among hepatologists a better understanding of the monocyte pathophysiology in relation to cirrhosis stages, and a therapeutic reconstitution of monocyte function are believed to enhance defence against infection and thus reduce morbidity and mortality of patients with cirrhosis in the future. By systematically delineating the heterogeneity and function of circulating monocytes ex vivo, we identified that the absence of CD52 expression on monocytes represented a distinct biomarker of monocyte dysfunction in patients with cirrhosis, discriminating patients at substantial risk for infectious complications. Otherwise, given the beneficial antimicrobial functions of CD52-expressing monocytes, CD52-stablisation may also represent such a target for immunotherapy worth exploring, at it has been desired in clinical practise. |
Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trial. In a Phase 2 double-blind, placebo-controlled, randomized clinical trial in cirrhosis with HE on maximal therapy, FMT regardless of dose, route, or donor was safe without any FMT-related adverse events. On post-hoc analysis, groups differed on HE recurrence, which was highest in the placebo-only group and linked with lower baseline Lachnospiraceae and reduced donor engraftment. |
Predictors of hepatic flares after nucleos(t)ide analogue cessation - Results of a global cohort study (RETRACT-B study). Multivariable analyses showed that older age (aHR 1.02, p = 0.001), male sex (aHR 1.57, p = 0.003), HBsAg levels at NA withdrawal (100-1,000 IU/ml; aHR 1.99, p IU/ml within the first 12 weeks. Clinical trial number not applicable. |
Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis. BLV 2 mg/day monotherapy up to 96 weeks was safe and effective in patients with HDV-related cirrhosis. Virological and clinical responses increased over time. Liver-related complications were few. |
Spliced exon9 ADRM1 promotes liver oncogenicity via selective degradation of tumor suppressor FBXW7. ADRM1-ΔEx9 redirects ubiquitin proteasome specificity to degrade the tumor suppressor protein FBXW7 selectively. This promotes HCC tumor formation and provides a synthetic lethal link for PARPi therapy. Impact and implications Reduced tumor suppressor protein FBXW7 expression is pivotal in HCC pathogenesis and other liver diseases. However, the regulatory mechanism governing FBXW7 protein expression remains elusive. Herein, we unveil a non-canonical spliced isoform of the ubiquitin receptor ADRM1 that selectively degrades FBXW7 protein, thereby promoting the premalignant transformation of hepatic cells and conferring growth advantages to HCC tumors. Furthermore, our results demonstrate that ADRM1-ΔEx9-expressing HCC tumors exhibited sensitivity to Olaparib in a dose-dependent manner, implicating the potential use of Olaparib in targeting ADRM1-ΔEx9-driven HCC growth. |
| J Neurogastroenterol Motil |
Association Between Functional Dyspepsia and Binge Eating Disorder: A Frequent, Often Overlooked Overlap Clinical Presentation. BED patients have a high prevalence of dyspepsia with an association between postprandial fullness and this eating disorder. BED appears to be more prevalent in younger individuals and males. These findings underscore the importance of considering dyspepsia in the management of BED and highlight the need for further research on this association. |
Baseline Impedance via Manometry Predicts Pathological Mean Nocturnal Baseline Impedance in Isolated Laryngopharyngeal Reflux Symptoms. Distal HRIM-BI from HRIM may potentially predict pathological MNBI in patients with ILPRS, but not in those with CTRS. Future outcome studies linked to the metric are warranted. |
Delayed Gastric Emptying Correlates With Decreased Post-prandial Motility in Children: A Single-center Retrospective Review. ADM findings differ between children with DGE and NGE. Children with DGE are more likely to have abnormal fasting phase III patterns and decreased post-prandial antral activity during ADM testing. |
Effect of Anti-reflux Mucosal Ablation on Esophageal Motility in Patients With Gastroesophageal Reflux Disease: A Study Based on High-resolution Impedance Manometry. ARMA effectively improves symptoms and reflux burden, EGJ barrier function, and esophageal body contractility in patients with PPIdependent GERD during short-term evaluation. Longer follow-up to clarify the sustainability of ARMA is needed. |
Predictors for the Development of Hypergastrinemia in Maintenance Treatment for Mild Gastroesophageal Reflux Disease Using a Half-dose Proton Pump Inhibitor. Old age, high baseline serum gastrin levels, and low baseline PG ratios are significant predictors of the development of hypergastrinemia in maintenance treatment for mild GERD using a half-dose PPI. |
The Esophageal Response to Distension on Functional Lumen Imaging Probe Panometry Is Minimally Changed by Conscious Sedation in Healthy Asymptomatic Subjects. While numeric differences in FLIP Panometry metrics were observed between sedated and awake FLIP in healthy subjects, these differences did not change the FLIP Panometry diagnosis. Sedated FLIP offers a well-tolerated method to assess esophageal motility during endoscopy. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Aliment Pharmacol Ther |
|---|
| Clin Gastroenterol Hepatol |
Lifestyle and Pharmacologic Approaches to Prevention of MASLD-related HCC. Selecting an appropriate anti-diabetic therapy for individuals with liver disease and diabetes may also decrease the occurrence of HCC. Metformin, PPAR activators, sodium-glucose cotransporter 2 (SGLT2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RA), aspirin, and statins have al shown promise to reduce the risk of HCC, although guidelines do not recommend their use for the sole purpose of chemoprevention at this time given a dearth of data defining their risk-benefit ratio. |
Point-of-care ultrasound in Gastroenterology and Hepatology. POCUS is most often used to answer focused clinical questions, supplement the traditional physical examination, and guide performance of invasive bedside procedures. This review describes several common POCUS applications used in gastroenterology and hepatology, as well as some novel applications that warrant further investigation. |
| Gastroenterology |
| J Hepatol |
Cellular interactions in self-directed immune mediated liver diseases. Our incomplete understanding of the mechanisms leading to breakdown in immunological self-tolerance and our inability to restore immune homeostasis hampers present progress in treatment. This review summarises recent advances in our understanding of the loss of hepatic tolerance and the cellular interactions leading to this, including immune cell invasion towards hepatocytes and biliary epithelial cells, checkpoint-induced immune-mediated liver injury (CHILI) and concludes with current progress in treatment strategies. |
| J Neurogastroenterol Motil |
Surgical and Therapeutic Interventions for Chronic Intestinal Pseudo-obstruction: A Scoping Review. Data pertaining to surgical therapy for CIPO is limited. Although this review suggests that surgical interventions for CIPO may be safe and effective for select patients, strong conclusions cannot be made due to limited number of relevant studies and small sample sizes. Concerted efforts to produce data from large studies on adults with CIPO are necessary. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Gastroenterol |
|---|
| Clin Gastroenterol Hepatol |
| Endoscopy |
| Gastroenterology |
| Gastrointest Endosc |
| Gut |
| Hepatology |
| J Hepatol |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Gastroenterology |
| Gut |
| J Hepatol |